Arohi Asset Management Liquidates DoubleVerify Position Amid Stock Decline

The Motley FoolThe Motley Fool
|||1 min read
Key Takeaway

Arohi Asset Management exits DoubleVerify stake entirely, selling 1.7 million shares for $20.6 million as the ad verification firm's stock tumbles 58.5% amid profitability concerns.

Arohi Asset Management Liquidates DoubleVerify Position Amid Stock Decline

Arohi Asset Management has completely divested its stake in ad verification firm DoubleVerify, selling 1.7 million shares for $20.6 million during the fourth quarter of 2025. The transaction marks a full exit from the software company at a time when DoubleVerify's stock has experienced significant depreciation.

DoubleVerify's equity has declined 58.5% over the past 12 months, reflecting investor concerns about the company's profitability trajectory despite maintaining top-line growth. While the company reported 16% revenue expansion in the period, net income contracted 35% year-over-year through the first nine months of 2025, signaling margin compression in core operations. The divergence between revenue growth and earnings deterioration has weighed on investor sentiment regarding the company's operational efficiency.

The exit by Arohi Asset Management joins a broader pattern of portfolio reassessment among institutional investors as software companies face elevated expectations for profitability alongside revenue growth. DoubleVerify's challenges underscore the ongoing pressure on enterprise software valuations in the current market environment.

Source: The Motley Fool

Back to newsPublished Feb 22

Related Coverage

GlobeNewswire Inc.

Corcept Therapeutics Faces Class Action Over FDA Rejection; Stock Crashed 50%

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant application. Stock plummeted 50.4% following December rejection. Investor deadline April 21, 2026.

CORT
Investing.com

D-Wave's 44% Plunge Masks Quantum Leap: Growth Story vs. Valuation Reality

D-Wave ($QBTS) fell 44% in 2026 despite strong bookings exceeding 2025 totals and $30M in major deals. Analysts see 132% upside, but 237x sales valuation remains extreme.

QBTS
GlobeNewswire Inc.

OneMain Holdings Faces Multi-State Securities Probe Over Alleged Lending Fraud

Pomerantz Law Firm investigates $OMF following multi-state lawsuit alleging deceptive lending practices. Stock tumbles 5.38% on fraud allegations.

OMF
GlobeNewswire Inc.

Boston Scientific Faces Securities Fraud Lawsuit Over Overstated EP Growth Claims

Boston Scientific faces class action lawsuit alleging material misstatements about electrophysiology growth. Stock fell 17.6% after disclosing slower market growth and competitive pressures.

BSX
GlobeNewswire Inc.

Nektar Therapeutics Faces Class Action Over Failed Trial Data Disclosure

Pomerantz LLP filed securities fraud class action against Nektar Therapeutics, alleging false statements about clinical trial enrollment procedures led to trial failure and stock decline.

NKTR
GlobeNewswire Inc.

Pomerantz Files Securities Fraud Suit Against $INO Over FDA Approval Misstatements

Pomerantz LLP sues Inovio Pharmaceuticals for alleged securities fraud over FDA approval misstatements. Stock fell 3.1% and 24.45% following manufacturing delays and accelerated approval rejection.

INO